Product Description
Sepranolone is a powerful neurological compound, produced naturally in the body, that modulates the effects of Allopregnanolone (ALLO). ALLO is a potent neurosteroid implicated in stress- and compulsion-related conditions ranging from Tourette to OCD, ADHD, compulsive gambling, PMDD and essential tremor. (Sourced from: https://asarinapharma.com/sepranolone/)
Mechanisms of Action: GABA Receptor Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Asarina Pharma
Company Location: OKLAHOMA CITY OK 73102
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Rett Syndrome|Tourette Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2021-001045-12 | P2 |
Active, not recruiting |
Rett Syndrome|Tourette Syndrome |
2023-02-22 |
|
APH205 | P2 |
Completed |
Tourette Syndrome|Rett Syndrome |
2023-02-01 |
32% |